• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace Home
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • Scopus İndeksli Yayınlar Koleksiyonu
  • View Item
  •   DSpace Home
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • Scopus İndeksli Yayınlar Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Severity and reversibility of smell-taste dysfunction in COVID-19 patients

xmlui.dri2xhtml.METS-1.0.item-rights

info:eu-repo/semantics/closedAccess

Date

2021

Author

Kant A.
Öztürk S.
Arslan M.
Ertunç B.
Çomoğlu Ş.
Karakoç H.N.
Yılmaz G.

Metadata

Show full item record

Abstract

Background: In SARS-COV-2 disease, anosmia and dysgeusia are symptoms that are usually detected together. In our study, it was aimed to investigate the impairments in the sense of smell and taste in our COVID-19 patients and to determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the parameters accompanying this impairment. Methods: The study was conducted retrospectively in patients with positive COVID-19 rtRT-PCR test, whose complaints of smell-taste dysfunction were questioned in 6 centers. Result: 8238 patients questioned for the impaired sense of smell and taste were included in our study. 1756 (21.3%) patients had smell-taste dysfunction. Smell dysfunction started 2.9±2.3 days after the onset of COVID-19 specific symptoms and continued for 9.4±2.7 days. There was a positive correlation between the disturbance of smell and taste and the complaints of fever, sore throat, myalgia, weakness, headache, and negative correlation the complaints of cough. 218 (12.4%) of the patients with smell-taste dysfunction stated that this complaint negatively affected their quality of life. Conclusion: Smell-taste dysfunction is more common, especially with the symptoms of upper respiratory tract infection of COVID-19, and has a positive correlation with fever, sore throat, myalgia, weakness, and headache, affects the quality of life of patients and improves in about 10-14 days. © 2021 A. CARBONE Editore. All rights reserved.

Volume

37

Issue

5

URI

https://doi.org/10.19193/0393-6384_2021_5_394
https://hdl.handle.net/20.500.12450/2951

Collections

  • Scopus İndeksli Yayınlar Koleksiyonu [1574]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Instruction | Guide | Contact |

DSpace@Amasya

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherCategoryLanguageAccess TypeThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherCategoryLanguageAccess Type

My Account

LoginRegister

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Instruction || Guide || Library || Amasya University || OAI-PMH ||

Amasya Üniversitesi Kütüphane ve Dokümantasyon Daire Başkanlığı, Amasya, Turkey
If you find any errors in content, please contact: openaccess@amasya.edu.tr

Creative Commons License
DSpace@Amasya by Amasya University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Amasya: